Cork – April 15, 2016 – Radisens announced today it has won the Red Herring Top 100 Europe award, a prestigious award honoring the year’s most promising private technology ventures from the European business region.
The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across Europe. The nominees were evaluated on 20 main quantitative and qualitative criterion: they include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.
This unique assessment of potential is complemented by a review of the actual track record and standing of a company, which allows Red Herring to see past the “buzz” and make the list a valuable instrument for discovering and advocating the greatest business opportunities in the industry. The nominees pitched their businesses at the Red Herring Europe Forum in Amsterdam on April 13 with the winners announced at the Gala Dinner that evening.
“This year was rewarding, beyond all expectations” said Alex Vieux, publisher and CEO of Red Herring. “There are many great companies producing really innovative and amazing products in Europe. We had a very difficult time narrowing the pool, shortlisting the finalists and selecting the winners. Radisens shows great promise and therefore deserves to win this award. We know that the 2016 crop will grow into some amazing companies that are sure to make an impact.”
Finalists for the 2016 edition of the Red Herring 100 Europe award were selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the months leading up to the announcement, Red Herring reviewed over 1200 companies in the telecommunications, security, cloud, software, hardware, biotech, healthcare, mobile and other industries completed their submissions to qualify for the award.
About Radisens Diagnostics
Radisens, a private venture-backed diagnostics company, is breaking new ground in the decentralisation of routine blood testing from central reference laboratories into physician offices, outpatient clinics, pharmacies and other near-patient test settings. With a finger-prick of blood, this multi-mode diagnostic device will return laboratory-grade results instantly within a patient’s physician visit.
Radisens’ initial menu concentrates on panels for those suffering with high-burden chronic disease resulting in improved patient outcomes and more efficient healthcare management. By integrating immunoassay, clinical chemistry, cell counting and other test modes, this near-patient device will finally open blood testing access to all with instant diagnosis and monitoring. The fear or needles, the many anxious days or weeks of waiting for results, the multiple physician visits, will all be things of the past.
